Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-18

Study Completion Date

2023-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will be conducted as a single-center, randomized, double-blind, placebo-controlled, ascending dose study in up to 4 sequential cohorts of healthy subjects. Each cohort will enroll 8 subjects: 6 subjects will receive ITI-333 and 2 subjects will receive placebo once daily for 14 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers

NCT04934124

Healthy Volunteers

COMPLETED PHASE1

Phase I Study of ICP-332 in Healthy Subjects

NCT06530966

Healthy Subjects

RECRUITING PHASE1

Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers

NCT00829582

Healthy Volunteers

COMPLETED PHASE1

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

NCT00599001

Healthy

COMPLETED PHASE1

A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

NCT05399030

Healthy Subjects

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Sequential ascending doses. Parallel (active, placebo) within each cohort

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1: 0.75 mg ITI-333 or placebo once daily for 14 days

Group Type EXPERIMENTAL

ITI-333

Intervention Type DRUG

ITI-333 oral solution

Placebo

Intervention Type OTHER

Matching placebo

Cohort 2: 1.5 mg ITI-333 or placebo once daily for 14 days

Group Type EXPERIMENTAL

ITI-333

Intervention Type DRUG

ITI-333 oral solution

Placebo

Intervention Type OTHER

Matching placebo

Cohort 3: 3 mg ITI-333 or placebo once daily for 14 days

Group Type EXPERIMENTAL

ITI-333

Intervention Type DRUG

ITI-333 oral solution

Placebo

Intervention Type OTHER

Matching placebo

Cohort 4: 6 mg ITI-333 or placebo once daily for 14 days

Group Type EXPERIMENTAL

ITI-333

Intervention Type DRUG

ITI-333 oral solution

Placebo

Intervention Type OTHER

Matching placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ITI-333

ITI-333 oral solution

Intervention Type DRUG

Placebo

Matching placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male and female subjects between 18 and 45 years old (inclusive);
* BMI inclusive of 18-32 kg/m2 at screening and a minimum weight of 50 kg;
* Willingness to remain in the clinic for the inpatient portion of the study and return for follow-up visit(s) as required by protocol and as deemed necessary by the Investigator.

Exclusion Criteria

* Clinically significant abnormality within 2 years of Screening that in the Investigator's opinion may place the subject at risk or interfere with study outcome variables; this includes, but is not limited to, history of or current cardiac, hepatic, renal, neurologic, GI, pulmonary, endocrinologic, hematologic, or immunologic disease or history of malignancy;
* Clinically significant abnormal findings in vital sign assessments, including blood oxygen saturation (SpO2) \< 96% and respiratory rate \< 12 breaths per min;
* History of psychiatric condition that in the Investigator's opinion may be detrimental to participation in the study;
* CRP, ESR, or fibrinogen that are above normal reference ranges at Screening or Day 1.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes